Epidermal growth factor binding sites in human pituitary macroadenomas

M. L. Jaffrain-Rea, E. Petrangeli, C. Lubrano, G. Minniti, D. Di Stefano, F. Sciarra, L. Frati, G. Tamburrano, G. Cantore, A. Gulino

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The number of epidermal growth factor (EGF) binding sites was determined by competitive binding assays in a series of 46 pituitary macroadenomas. A single concentration of 125I-EGF (1 nM) was used for all experiments. In four cases, a displacement curve was obtained by adding increasing concentrations of cold EGF, and Scatchard analysis showed the presence of two classes of EGF binding sites, with K(d1)=0.62 ± 0.23 nM and K(d2)=53.8 ± 8.2 nM for the high- and low-affinity binding sites respectively. The distribution of EGF binding sites was studied in 42 cases by a single-point assay, in the presence and in the absence of a 100-fold cold EGF excess. A non-parametric distribution of EGF binding sites was observed (median 10.2 fmol/mg membrane protein, range 0.0-332.0). EGF-receptor positivity, defined as EGF binding ≤10.0 fmol/mg protein, was observed in 23 samples (54.8%), especially in prolactinomas (76.5%, P3H]methyltrienolone. No correlation could be found between EGF binding and either the gender and gonadal status of the patients, or the expression of SSRs by the adenomas. We conclude that the EGF family of growth factors may play a role in the evolution of a significant subset of human pituitary adenomas, especially in their invasiveness, and that a high EGF binding capacity may represent an additional marker of aggressiveness for these tumors. Sex steroids do not appear to have a significant role in the regulation of EGF binding in vivo in these tumors.

Original languageEnglish
Pages (from-to)425-433
Number of pages9
JournalJournal of Endocrinology
Volume158
Issue number3
Publication statusPublished - Sep 1998

Fingerprint

Epidermal Growth Factor
Binding Sites
Metribolone
Prolactinoma
Competitive Binding
Pituitary Neoplasms
Tumor Biomarkers
Epidermal Growth Factor Receptor
Adenoma
Intercellular Signaling Peptides and Proteins
Membrane Proteins
Steroids

ASJC Scopus subject areas

  • Endocrinology

Cite this

Jaffrain-Rea, M. L., Petrangeli, E., Lubrano, C., Minniti, G., Di Stefano, D., Sciarra, F., ... Gulino, A. (1998). Epidermal growth factor binding sites in human pituitary macroadenomas. Journal of Endocrinology, 158(3), 425-433.

Epidermal growth factor binding sites in human pituitary macroadenomas. / Jaffrain-Rea, M. L.; Petrangeli, E.; Lubrano, C.; Minniti, G.; Di Stefano, D.; Sciarra, F.; Frati, L.; Tamburrano, G.; Cantore, G.; Gulino, A.

In: Journal of Endocrinology, Vol. 158, No. 3, 09.1998, p. 425-433.

Research output: Contribution to journalArticle

Jaffrain-Rea, ML, Petrangeli, E, Lubrano, C, Minniti, G, Di Stefano, D, Sciarra, F, Frati, L, Tamburrano, G, Cantore, G & Gulino, A 1998, 'Epidermal growth factor binding sites in human pituitary macroadenomas', Journal of Endocrinology, vol. 158, no. 3, pp. 425-433.
Jaffrain-Rea ML, Petrangeli E, Lubrano C, Minniti G, Di Stefano D, Sciarra F et al. Epidermal growth factor binding sites in human pituitary macroadenomas. Journal of Endocrinology. 1998 Sep;158(3):425-433.
Jaffrain-Rea, M. L. ; Petrangeli, E. ; Lubrano, C. ; Minniti, G. ; Di Stefano, D. ; Sciarra, F. ; Frati, L. ; Tamburrano, G. ; Cantore, G. ; Gulino, A. / Epidermal growth factor binding sites in human pituitary macroadenomas. In: Journal of Endocrinology. 1998 ; Vol. 158, No. 3. pp. 425-433.
@article{d49d54adbf4c4098993feebe65072818,
title = "Epidermal growth factor binding sites in human pituitary macroadenomas",
abstract = "The number of epidermal growth factor (EGF) binding sites was determined by competitive binding assays in a series of 46 pituitary macroadenomas. A single concentration of 125I-EGF (1 nM) was used for all experiments. In four cases, a displacement curve was obtained by adding increasing concentrations of cold EGF, and Scatchard analysis showed the presence of two classes of EGF binding sites, with K(d1)=0.62 ± 0.23 nM and K(d2)=53.8 ± 8.2 nM for the high- and low-affinity binding sites respectively. The distribution of EGF binding sites was studied in 42 cases by a single-point assay, in the presence and in the absence of a 100-fold cold EGF excess. A non-parametric distribution of EGF binding sites was observed (median 10.2 fmol/mg membrane protein, range 0.0-332.0). EGF-receptor positivity, defined as EGF binding ≤10.0 fmol/mg protein, was observed in 23 samples (54.8{\%}), especially in prolactinomas (76.5{\%}, P3H]methyltrienolone. No correlation could be found between EGF binding and either the gender and gonadal status of the patients, or the expression of SSRs by the adenomas. We conclude that the EGF family of growth factors may play a role in the evolution of a significant subset of human pituitary adenomas, especially in their invasiveness, and that a high EGF binding capacity may represent an additional marker of aggressiveness for these tumors. Sex steroids do not appear to have a significant role in the regulation of EGF binding in vivo in these tumors.",
author = "Jaffrain-Rea, {M. L.} and E. Petrangeli and C. Lubrano and G. Minniti and {Di Stefano}, D. and F. Sciarra and L. Frati and G. Tamburrano and G. Cantore and A. Gulino",
year = "1998",
month = "9",
language = "English",
volume = "158",
pages = "425--433",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "BioScientifica Ltd.",
number = "3",

}

TY - JOUR

T1 - Epidermal growth factor binding sites in human pituitary macroadenomas

AU - Jaffrain-Rea, M. L.

AU - Petrangeli, E.

AU - Lubrano, C.

AU - Minniti, G.

AU - Di Stefano, D.

AU - Sciarra, F.

AU - Frati, L.

AU - Tamburrano, G.

AU - Cantore, G.

AU - Gulino, A.

PY - 1998/9

Y1 - 1998/9

N2 - The number of epidermal growth factor (EGF) binding sites was determined by competitive binding assays in a series of 46 pituitary macroadenomas. A single concentration of 125I-EGF (1 nM) was used for all experiments. In four cases, a displacement curve was obtained by adding increasing concentrations of cold EGF, and Scatchard analysis showed the presence of two classes of EGF binding sites, with K(d1)=0.62 ± 0.23 nM and K(d2)=53.8 ± 8.2 nM for the high- and low-affinity binding sites respectively. The distribution of EGF binding sites was studied in 42 cases by a single-point assay, in the presence and in the absence of a 100-fold cold EGF excess. A non-parametric distribution of EGF binding sites was observed (median 10.2 fmol/mg membrane protein, range 0.0-332.0). EGF-receptor positivity, defined as EGF binding ≤10.0 fmol/mg protein, was observed in 23 samples (54.8%), especially in prolactinomas (76.5%, P3H]methyltrienolone. No correlation could be found between EGF binding and either the gender and gonadal status of the patients, or the expression of SSRs by the adenomas. We conclude that the EGF family of growth factors may play a role in the evolution of a significant subset of human pituitary adenomas, especially in their invasiveness, and that a high EGF binding capacity may represent an additional marker of aggressiveness for these tumors. Sex steroids do not appear to have a significant role in the regulation of EGF binding in vivo in these tumors.

AB - The number of epidermal growth factor (EGF) binding sites was determined by competitive binding assays in a series of 46 pituitary macroadenomas. A single concentration of 125I-EGF (1 nM) was used for all experiments. In four cases, a displacement curve was obtained by adding increasing concentrations of cold EGF, and Scatchard analysis showed the presence of two classes of EGF binding sites, with K(d1)=0.62 ± 0.23 nM and K(d2)=53.8 ± 8.2 nM for the high- and low-affinity binding sites respectively. The distribution of EGF binding sites was studied in 42 cases by a single-point assay, in the presence and in the absence of a 100-fold cold EGF excess. A non-parametric distribution of EGF binding sites was observed (median 10.2 fmol/mg membrane protein, range 0.0-332.0). EGF-receptor positivity, defined as EGF binding ≤10.0 fmol/mg protein, was observed in 23 samples (54.8%), especially in prolactinomas (76.5%, P3H]methyltrienolone. No correlation could be found between EGF binding and either the gender and gonadal status of the patients, or the expression of SSRs by the adenomas. We conclude that the EGF family of growth factors may play a role in the evolution of a significant subset of human pituitary adenomas, especially in their invasiveness, and that a high EGF binding capacity may represent an additional marker of aggressiveness for these tumors. Sex steroids do not appear to have a significant role in the regulation of EGF binding in vivo in these tumors.

UR - http://www.scopus.com/inward/record.url?scp=0031708554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031708554&partnerID=8YFLogxK

M3 - Article

C2 - 9846172

AN - SCOPUS:0031708554

VL - 158

SP - 425

EP - 433

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 3

ER -